Chief Corporate Affairs Officer
Kathleen W. Tregoning has served as our Chief Corporate Affairs Officer since July 2020 and additionally became our Head of Commercial Strategy in September 2023.
In her role at Cerevel, Ms. Tregoning oversees and aligns critical external-facing functions responsible for managing Cerevel’s brand and reputation with key stakeholders. Her scope of responsibility includes investor relations, internal and external communications, patient advocacy, public policy, commercial insights & analytics, market access, strategic marketing, and new product planning.
Prior to joining Sanofi, Ms. Tregoning spent more than 10 years at Biogen, first as vice president, public policy & government affairs, and then as senior vice president, corporate affairs. Ms. Tregoning also worked as a professional staff member in the United States Congress, where she held health policy roles with the Senate Budget Committee, the House Energy & Commerce Committee, and the House Ways & Means Committee.
Ms. Tregoning currently serves on the Board of Directors of Spero Therapeutics. She graduated from Stanford University with B.A. in International Relations and holds M.A. in Public Policy from the Harvard Kennedy School.